XML 72 R55.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT REPORTING (Details) - USD ($)
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Research and development $ 2,212,000 $ 2,520,000
General and administrative 3,243,181 3,903,191
Cash used in operating activities (7,645,532) (10,129,810)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Research and development [1] 2,212,000 2,520,000
General and administrative [2] 3,243,000 3,903,000
Cash used in operating activities [3] $ 7,646,000 $ 10,130,000
[1] Research and development expenses consist primarily of costs related to laboratory operations, clinical trial execution, investigational device testing, design iterations, and personnel-related expenses associated with research activities. These costs are not confined to a single financial statement line item and may be classified within general and administrative expense, professional fees, or payroll, depending on their nature. These expenses are regularly reviewed by the CODM as a single category for internal decision-making purposes.
[2] General and administrative expense includes overhead, clinical trial-related administrative and planning costs, and manufacturing-related costs such as raw materials. These are not separately reviewed by the CODM and are assessed as part of the broader G&A category for decision-making purposes.
[3] Cash used in operating activities is a key metric monitored by the CODM in evaluating resource needs, development pacing, and investment feasibility in the absence of revenue.